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Background: Contrast-induced nephropathy (CIN) in native kidneys is associated with 
a significant increase in mortality and morbidity. Data regarding CIN in renal allografts 
are limited, however. We retrospectively studied CIN in renal allografts at our institution: 
its incidence, risk factors, and effect on long-term outcomes including allograft loss and 
death.
Methods: One hundred thirty-five renal transplant recipients undergoing 161 contrast- 
enhanced computed tomography (CT) scans or coronary angiograms (Cath) between 
years 2000 and 2014 were identified. Contrast agents were iso- or low osmolar. CIN was 
defined as a rise in serum creatinine (SCr) by >0.3 mg/dl or 25% from baseline within 
4 days of contrast exposure. After excluding 85 contrast exposures where patients had 
no SCr within 4 days of contrast administration, 76 exposures (CT: n = 45; Cath: n = 31) 
in 50 eligible patients were analyzed. Risk factors assessed included demographics, 
comorbid conditions, type/volume of contrast agent used, IV fluids, N-acetylcysteine 
administration, and calcineurin inhibitor use. Bivariate and multivariable analyses were 
used to assess the risk of CIN.
results: Incidence of CIN was 13% following both, CT (6 out of 45) and Cath (4 out of 31). 
Significant bivariate predictors of CIN were IV fluid administration ( p =  0.05), lower 
hemoglobin ( p = 0.03), and lower albumin ( p = 0.02). In a multivariable model, CIN was 
predicted by N-acetylcysteine ( p = 0.03) and lower hemoglobin ( p = 0.01). Calcineurin 
inhibitor use was not associated with CIN. At last follow-up, CIN did not affect allograft 
or patient survival.
conclusion: CIN is common in kidney transplant recipients, and there is room for quality 
improvement with regards to careful renal function monitoring post-contrast exposure. In 
our study, N-acetylcysteine exposure and lower hemoglobin were associated with CIN. 
Calcineurin inhibitor use was not associated with CIN. Our sample size is small, however, 
and larger prospective studies of CIN in renal allografts are needed.
Keywords: contrast nephropathy, transplant, aKi, calcineurin inhibitors, kidney
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inTrODUcTiOn
Since contrast-induced nephropathy (CIN) was recognized 
more than 70  years ago, there have been continuous efforts to 
chemically modify iodine contrast media (CM) to become less 
nephrotoxic (1). Although CM have become safer, which reduces 
the likelihood of CIN per procedure, the indications for their 
use have dramatically increased. Over the last two decades, the 
utilization of computed tomography (CT) scanning and coro-
nary angiograms (Cath) have increased by about 800 and 400%, 
respectively, with currently about 1.2 million Caths performed in 
the US annually and over 80 million CM doses delivered world-
wide (2, 3). Furthermore, the number of patients with CIN risk 
factors, such as chronic renal insufficiency (CRI), diabetes, and 
congestive heart failure, has also grown. Currently, more than 27 
million people are estimated to have CRI in the United States, and 
200 million have diabetes worldwide (4, 5). The combination of 
increased CM administration frequency and greater prevalence 
of at-risk patients is likely to result in a continuing increase in CIN 
events. The incidence of CIN varies between studies, depending 
on risk factors of the cohort and definition of CIN, but figures 
have been reported to be as high as 50% in studies enriched with 
CRI and diabetic patients.
CIN is associated with a significant increase in mortality 
and morbidity in patients with native kidneys. After adjusting 
for comorbid factors, a retrospective study of 7,586 patients 
showed a significant increase in in-hospital and long-term 
mortality in patients who developed CIN (6). Another study 
of 1,826 patients, who underwent coronary artery intervention 
procedures, showed that 14% developed CIN and 1% required 
hemodialysis. Mortality was 1% in patients who did not develop 
CIN versus 7% in those with CIN, and 36% in the hemodialysis-
treated CIN group (7). Moreover, studies by several other 
groups also support the position that CIN is associated with 
increased in-hospital and long-term mortality (8–10). Given 
the enhanced mortality and morbidity associated with CIN, 
several groups have been studying the pathophysiology of CIN, 
determining associated risk factors and investigating strategies 
for preventing it.
Although published papers studying CIN in native kidneys 
are abundant in the medical literature, data pertinent to CIN 
in renal allografts are relatively scarce (11–15). Moreover, it 
is plausible that renal transplant recipients is at a particularly 
higher risk for developing CIN due to aspects that are unique 
to renal allografts such as immunosuppression, lack of sympa-
thetic innervation, glomerular hyperfiltration, and burden of 
cardiovascular disease. As a result, a better understanding of the 
incidence and predictors of CIN in renal transplant recipients is 
warranted.
In this retrospective study, we report the incidence of CIN in 
renal transplant recipients, its associated risk factors, and effect 
on long-term outcomes including allograft loss and death (16).
MaTerials anD MeThODs
This is a retrospective observational study that was approved by 
the University of Cincinnati (UC) Institutional Review Board 
in April 2013. All angiograms and other CM-enhanced studies 
performed on renal transplant recipients hospitalized between 
January 1st of 2000 and March 31st of 2014 were considered for 
the final analysis.
Data extraction, entry, and storage
After obtaining a list of all transplant recipients from the UC 
Medical Center prospective transplant database, subjects exposed 
to CM were identified by manually reviewing our institution’s 
electronic medical records including radiology and cardiac Cath 
lab records. After the list of CM recipients was completed, multiple 
variables including clinical data, laboratory results, and comorbid 
conditions were obtained and recorded in a password-protected 
Microsoft Excel format prior to converting to statistical output 
files. The choice of the variables was based on availability of the 
data, the prevalent knowledge related to risk factors of CIN, in 
addition to transplant-unique variables that might be associated 
with CIN (Table  1). The transplant- and immunosuppression-
related data were imported from the transplant master database. 
The rest of the variables were obtained from the UC Medical 
Center electronic medical records. Since this was a retrospective 
record review, the study protocol did not influence the standard 
medical care received by the patients.
Definition of cin
CIN was defined as a rise in serum creatinine (SCr) by >0.3 mg/dl 
or 25% from baseline within 4 days of CM exposure.
inclusion/exclusion criteria
All patients with functioning renal allografts and exposure to CM 
for cardiac or peripheral angiograms, contrasted CT scans, intra-
venous pyelograms, or any other CM-requiring intervention/study 
during their hospitalization at the UC Medical Center from January 
1st of 2000 to March 31st of 2014 were eligible. Patients with no 
SCr available within 4 days post-CM exposure were excluded.
statistical analysis
Descriptive statistics included means ± SDs for continuous vari-
ables and proportions and counts for categorical variables. All but 
three p-values were obtained from Generalized Linear Models 
employing Generalized Estimating Equations to account for clus-
tering of multiple exposures within a patient. The remaining three 
tests (see Table 1) were performed where some cell frequencies 
were 0 or 100%—these were Fisher’s exact tests. p-Values associ-
ated with graft age and follow-up duration were based on logs of 
the raw values. A multivariable model with CIN as the dependent 
variable was constructed by starting with all relevant bivariate pre-
dictors associated with CIN at p < 0.20, then applying backward 
elimination of the weakest adjusted predictors until all remaining 
predictors had p < 0.05 in the presence of the other remaining 
predictors. The study alpha was a two-tailed p = 0.05, unadjusted 
for multiple tests, and all analyses were conducted using SAS 9.4.
resUlTs
Out of 161 CM exposures, 85 were excluded for not meeting 
inclusion/exclusion criteria. Fifty patients with 76 exposures 
TaBle 1 | Baseline characteristics of patients with contrast media (cM) exposure.
all exposures 
(N = 76)
contrast-induced nephropathy (cin) 
(N = 10)
no cin  
(N = 66)
p-Value
Gender (male) 50 (38) 30 (3) 53 (35) 0.18
Race (African-American) 16 (12) 30 (3) 14 (9) 0.31
Smoker 9 (7) 20 (2) 8 (5) 0.32
Diabetes 32 (24) 30 (3) 32 (21) 0.89
Hypertension 78 (59) 80 (8) 77 (51) 0.83
Congestive heart failure 7 (5) 10 (1) 6 (4) 0.69
Coronary artery disease 24 (18) 10 (1) 26 (17) 0.21
Hypotension (on day of contrast exposure) 8 (6) 20 (2) 6 (4) 0.30
ACE-I/ARB 17 (13) 10 (1) 18 (12) 0.47
Computed tomography versus Cath 59 (45) 60 (6) 59 (39) 0.95
CM groups 0.54
Low-osmolar CM 75 (57) 90 (9) 73 (48) –
Isoosmolar CM 21 (16) 10 (1) 23 (15) –
Non-ionic CM 4 (3) 0 5 (3) –
IV fluid administration 53 (40) 80 (8) 48 (32) 0.048
N-acetylcysteine administration 36 (27) 60 (6) 32 (21) 0.09
Tacrolimus 70 (53) 80 (8) 68 (45) 0.36
Cyclosporine 13 (10) 20 (2) 12 (8) 0.40
Calcineurin inhibitor 83 (63) 100 (10) 80 (53) 0.20
Mycophenolate 97 (74) 100 (10) 97 (64) 1.00
Live donor kidney recipient 78 (59) 70 (7) 79 (52) 0.56
Allograft loss 9 (7) 10 (1) 9 (6) 0.93
Patient death 11 (8) 10 (1) 11 (7) 0.94
Age (years) 53.3 ± 15.4 49.6 ± 13.9 53.9 ± 15.6 0.41
Weight (kg) 82.0 ± 21.5 74.1 ± 31.3 83.2 ± 19.7 0.40
Height (") 68.1 ± 4.0 67.0 ± 4.5 68.2 ± 3.9 0.47
BMI (kg/m2) 27.2 ± 5.6 24.9 ± 6.8 27.5 ± 5.4 0.27
Baseline serum creatinine (SCr) (mg/dl) 1.47 ± 0.88 1.5 ± 0.92 1.5 ± 0.88 0.86
Post-contrast SCr peak (days 1–4) (mg/dl) 1.47 ± 0.85 2.1 ± 1.0 1.4 ± 0.79 0.055
SCr on most recent follow-up (mg/dl) 1.65 ± 1.2 1.9 ± 1.5 1.6 ± 1.2 0.61
Follow-up duration (months) 25.3 ± 24.7 33.4 ± 33.8 24.1 ± 23.1 0.91
Contrast volume (ml) (N = 72) 134 ± 69 122 ± 49 (N = 10) 136. ± 72 (N = 62) 0.45
Hemoglobin (g/dl) 10.3 ± 2.3 8.9 ± 2.1 10.5 ± 2.3 0.03
Albumin (g/dl) (N = 69) 3.5 ± 0.6 3.1 ± 0.49 (N = 9) 3.5 ± 0.62 (N = 60) 0.02
Graft age (days) 971 ± 1,103 1,013 ± 1,193 966 ± 1,099 0.78
Tacrolimus trough (ng/ml) (N = 47) 8.6 ± 5.2 10.5 ± 5.6 (N = 7) 8.3 ± 5.1 (N = 40) 0.37
Cyclosporine trough (ng/ml) (N = 10) 79 ± 19 89 ± 71 (N = 2) 76 ± 20 (N = 8) 0.16
Total of 76 exposures in 50 patients. Numbers are % (count) or mean ± SD. Most significance tests are from Generalized Linear Models using Generalized Estimating Equations to 
account for multiple exposures in single patients. Tests for three CM groups, calcineurin inhibitors, and mycophenolate are Fisher’s exact tests not accounting for multiple exposures. 
Graft age and follow-up duration p-values are based on log-transformed raw values.
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(45 CT and 31 Cath) were analyzed. For 73 exposures, baseline 
SCr was established less than 4 months prior to exposure, while 
three baseline SCrs were established more than 4  months 
prior. Counting exposures (rather than patients), 50% were 
in male patients, 16% were in African-American patients, 9% 
were in smokers, 32% had diabetes, 78% had hypertension, 
24% had coronary artery disease, 7% congestive heart failure, 
and 17% were on an ACE inhibitor. Seventy eight percent of 
exposures were in patients received living donor kidneys. 
Maintenance immunosuppression included tacrolimus in 
70%, cyclosporine in 13%, and mycophenolate in 97% of the 
exposures (Table 1).
At the time of CM exposure, the (mean, ±SD) age of 
the patients was 53  ±  15  years, baseline SCr, 1.5  ±  0.9  mg/
dl, hemoglobin 10.3 ±  2.3  g/dl, and albumin 3.5 ±  0.6  g/dl. 
Tacrolimus 12-h trough was 8.6 ± 5.2 ng/ml, cyclosporine 12-h 
trough was 79.1  ±  19.2  ng/ml, and 8% of the patients were 
hypotensive (SBP < 100 mm Hg). IV fluids and N-acetylcysteine 
were administered in 53 and 36% of the patients, respectively 
(Table  1). The overall incidence of CIN was 13% (10 out of 
76 exposures), equally so in patients who underwent Cath 
(4 out of 31 exposures) and in patients who received CM-enhanced 
CT scans (6 out of 45 exposures) (Figure 1).
Significant simple bivariate predictors of CIN were IV 
fluid administration (p =  0.05), lower hemoglobin (p =  0.03), 
and lower albumin (p =  0.02). Female gender (p =  0.18) and 
N-acetylcysteine administration (p = 0.09) also made the cutoff 
to be included as candidate predictors in a multivariable model. 
After these five predictors were entered into a multivariable 
prediction model and subjected to backwards selection, lower 
hemoglobin (p =  0.01) and N-acetylcysteine (p =  0.03) were 
associated with CIN (Table 2).
Calcineurin inhibitor use was not associated with CIN. CIN 
was not associated with allograft loss or death on last follow-up, 
with last follow-up occurring (mean ± SD) 25 ± 24 months after 
exposure.
TaBle 2 | Predictors of contrast-induced nephropathy (cin).
Odds ratio (confidence interval) p-Value
N-acetylcysteine administration 9.0 (2.7–29.9) 0.03
Hemoglobin per unit (g/dl) 0.55 (0.32–0.93) 0.01
Significant predictors of CIN (p < 0.05) after a multivariable model with CIN as the 
dependent variable.
FigUre 1 | contrast-induced nephropathy (cin) frequency. Total 
number (N) of contrast media (CM) exposures = 76, N of CM exposures via 
computed tomography (CT) = 45, N of CM exposures via coronary 
angiogram (Cath) = 31.
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DiscUssiOn
It is plausible that renal transplant recipients are at a particularly 
high risk for developing CIN. In addition to all the traditional 
risk factors associated with CIN in native kidneys, the following 
aspects are unique to renal allografts:
 i. Immunosuppressive regimens often include calcineurin 
inhibitors, which harbor a significant risk of nephrotoxicity. 
Calcineurin inhibitor nephrotoxicity is mediated by several 
mechanisms including afferent arteriolar vasoconstriction, 
peripheral arteriolar hyalinosis, isometric vacuolization of 
tubular epithelial cells, stripped interstitial fibrosis, and 
thrombotic microangiopathy, all of which might predispose 
to CIN (17).
 ii. Mycophenolate mofetil (MMF)/mycophenolate sodium 
(MPA), an inosine monophosphate dehydrogenase inhibi-
tor, is another medication that together with calcineurin 
inhibitors forms the backbone of modern maintenance 
immunosuppression regimens. MMF/MPA has been shown 
to ameliorate the production of reactive oxygen species 
(ROS) in hepatic ischemia reperfusion injury in Wistar rats 
(18). Moreover, mycophenolate has been shown to neutralize 
the calcineurin inhibitor effect in enhancing phenylephrine-
induced vasoconstriction of abdominal aorta allografts in 
Lewis rats. This has been mediated by an increase in the 
endothelial nitric oxide (NO) synthase activity (19).
CIN is mediated by an interplay of various factors that 
increase vasoconstriction and mitigate vasodilatation, 
leading to renal medullary hypoxia and acute tubular 
necrosis. Furthermore, CM administration accentuates the 
production of ROS. ROS then cause direct damage of the 
tubular epithelial cells and scavenge NO leading to further 
arteriolar vasoconstriction (20, 21). Therefore, based on our 
current understanding of the pathophysiology of CIN and 
the preclinical data demonstrating a negative effect of MMF/
MPA on ROS, we speculate that MMF/MPA might have a 
protective role in CIN.
 iii. Renal allografts lack sympathetic innervation that is normally 
responsible for a significant portion of sodium and water reten-
tion in the proximal tubules. As a result, transplant recipients 
might be prone to develop hemodynamic-mediated acute 
allograft insufficiency secondary to a decrease in the effective 
arterial circulating volume. Intrarenal hemodynamic changes 
in kidney allografts have been evaluated. A study compared 
resistive indices (RI), measured by Doppler studies, of donor 
kidneys with their subsequent RI in recipients. RI, used as a 
surrogate for intrarenal vascular impedance, improved after 
transplantation reflecting an increase in renal blood flow to 
maintain GFR (22). The authors explain their finding by the 
lack of sympathetic innervation in renal allografts. Given the 
effect of the sympathetic nervous system on systemic and 
renal hemodynamics, denervated allografts might have a 
different CIN susceptibility profile when compared to native 
kidneys.
 iv. Renal allografts hyperfiltrate, undergo hemodynamic stress, 
and develop maladaptive structural changes. Therefore, 
despite maintaining near normal GFR by virtue of maximiz-
ing various compensatory mechanisms, renal allografts often 
have significantly reduced renal reserve. This makes them 
more prone for renal insults including CIN.
 v. In addition to the burden of cardiovascular disease lead-
ing to frequent coronary and peripheral angiograms, renal 
transplant recipients are immunosuppressed and at a higher 
risk for developing infections and malignancies, diagnosis of 
which often requires CM-enhanced studies.
Although CIN in native kidneys has been studied extensively, 
only few small retrospective studies addressed CIN in renal 
allografts (11–15). In a retrospective study of 35 renal transplant 
recipients on cyclosporine, the incidence of CIN defined by a 
rise in SCr by >25% was 21% (12). This is higher than the 13% 
CIN incidence seen in native kidneys; however, six out of the 
seven patients developing CIN received 1/2 normal saline or 
no IV fluids for prophylaxis as opposed to standard of care iso-
tonic fluid administration (23). In another paper of 57 patients 
undergoing coronary angiograms, CIN defined as a rise in SCr 
by >25% or 0.5 mg/dl within 3 days post-Cath occurred in 16% 
of the patients (11). Univariate comparisons showed that the use 
of N-acetylcysteine and isoosmolar CM were protective. Logistic 
regression analysis, however, revealed that only low osmolarity 
CM administration was associated with CIN compared to isoos-
molar CM (odds ratio of ~7.7). Type of renal graft, preexisting 
comorbidities, and immunosuppressive medications were not 
associated with CIN. Neither of the two mentioned studies 
looked at hard outcomes such as death-censored allograft loss 
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or death. More recently, three small studies reported a CIN 
incidence of 6–13% (13–15). In one study, CIN occurred in 13% 
of renal transplant recipients undergoing endovascular aortic 
aneurysm repair versus 5% in a non-transplanted comparison 
group (14).
In our study of transplant recipients receiving CT or Cath, the 
incidence of CIN was 13%, which is consistent with what was 
published and reproduced before in both native and transplant 
kidneys (11, 14, 23). Anemia was independently associated 
with CIN, which is consistent with previous reports (24). This is 
biologically plausible since anemia can exacerbate hemodynamic 
stress and ischemia reperfusion-related acute kidney injury 
particularly in solitary allografts whose hemodynamic com-
pensatory mechanisms are already exhausted. N-acetylcysteine 
use positively correlated with CIN, which contradicts multiple 
previous studies that showed it had a protective effect (25, 26). 
This protective effect of N-acetylcysteine, however, could not be 
reproduced in multiple subsequent trials including a very well-
designed randomized controlled trial. In this prospective trial of 
2,308 patients with risk factors for CIN, N-acetylcysteine failed 
to have a protective effect (23). An alternative explanation for 
our finding could be that N-acetylcysteine was given to patients 
who were considered by the treating physician as high risk for 
developing CIN. Therefore, we should be cautious inferring that 
N-acetylcysteine use is a predictive marker of CIN given the pos-
sibility of indication bias that exists in retrospective analyses. We 
anticipated that intravenous fluid administration will have a pro-
tective effect, which would persist after multivariable modeling, 
but this did not occur. We attribute this to the small sample size 
and potential underlying bias that could not be accounted for in 
a retrospective design.
We did not observe any safety signal related to calcineurin 
inhibitor use, and we could not assess any potential protective 
effect of mycophenolate since 97% of patients were on it.
We acknowledge that our study has several limitations. First, 
it is a small and retrospective study. Second, we did not capture 
CM-enhanced studies done as outpatient procedures or at outside 
hospitals. Third, we did not exclude acute kidney injury episodes 
that occurred early after transplantation. This could overestimate 
the incidence of CIN since early acute allograft failure could be 
confounded by several factors including rejection.
In conclusion, CIN is common in renal transplant recipients 
receiving both intra-arterial and intravenous CM. Therefore, 
there is room for careful risk stratification, optimizing hemody-
namics and avoiding further potential nephrotoxins in transplant 
recipients receiving CM-enhanced studies. Prospective controlled 
studies of CIN in transplant settings are warranted.
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